These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17562516)

  • 41. [Ultrasound screening and diagnosis of fetal structural abnormalities between 11-14 gestational weeks].
    Markov D; Chernev T; Dimitrova V; Mazneĭkova V; Leroy Y; Jacquemyn Y; Ramaekers P; Van Bulck B; Loquet P
    Akush Ginekol (Sofiia); 2004; 43(3):3-10. PubMed ID: 15341249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased nuchal translucency and fetal chromosomal defects.
    Mol BW; Pajkrt E; Bilardo CM
    N Engl J Med; 1998 Apr; 338(17):1229; author reply 1229-30. PubMed ID: 9556395
    [No Abstract]   [Full Text] [Related]  

  • 43. Threshold of nuchal translucency for the detection of chromosomal aberration: comparison of different cut-offs.
    Kim MH; Park SH; Cho HJ; Choi JS; Kim JO; Ahn HK; Shin JS; Han JY; Kim MY; Yang JH
    J Korean Med Sci; 2006 Feb; 21(1):11-4. PubMed ID: 16479057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased fetal nuchal translucency at 11-14 weeks.
    Nicolaides KH; Heath V; Cicero S
    Prenat Diagn; 2002 Apr; 22(4):308-15. PubMed ID: 11981911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Second-trimester prenatal screening for trisomy 21 using biochemical markers: a 7-year experience in one cytogenetic laboratory.
    Marical H; Douet-Guilbert N; Bages K; Collet M; Le Bris MJ; Morel F; De Braekeleer M
    Prenat Diagn; 2006 Apr; 26(4):308-12. PubMed ID: 16491510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repeatability of measurement of fetal nuchal translucency thickness.
    Pandya PP; Altman DG; Brizot ML; Pettersen H; Nicolaides KH
    Ultrasound Obstet Gynecol; 1995 May; 5(5):334-7. PubMed ID: 7614139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First-trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age.
    Szabó J; Gellén J; Szemere G
    Ultrasound Obstet Gynecol; 1995 Mar; 5(3):161-3. PubMed ID: 7788489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia.
    Zoppi MA; Ibba RM; Floris M; Monni G
    Ultrasound Obstet Gynecol; 2001 Dec; 18(6):649-51. PubMed ID: 11844208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
    Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses.
    Michailidis GD; Economides DL
    Ultrasound Obstet Gynecol; 2001 Feb; 17(2):102-5. PubMed ID: 11251915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased Fetal Nuchal Translucency - Also a Risk for a Rare Submicroscopic Chromosomal Abnormalities.
    Tercanli S; Miny P; Filges I
    Ultraschall Med; 2015 Oct; 36(5):419-20. PubMed ID: 26759849
    [No Abstract]   [Full Text] [Related]  

  • 53. Fetal chromosomal abnormalities: antenatal screening and diagnosis.
    Anderson CL; Brown CE
    Am Fam Physician; 2009 Jan; 79(2):117-23. PubMed ID: 19178062
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nuchal translucency and nasal bone for trisomy 21 screening: single center experience.
    Monni G; Zoppi MA; Ibba RM; Floris M; Manca F; Axiana C
    Croat Med J; 2005 Oct; 46(5):786-91. PubMed ID: 16158472
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nuchal translucency thickness in fetuses with chromosomal translocation at 11-12 weeks of gestation.
    Cheng PJ; Chang SD; Shaw SW; Soong YK
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1058-62. PubMed ID: 15863545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nuchal translucency: association of size and persistence with fetal abnormalities.
    Fukada Y; Yasumizu T; Hoshi K
    Int J Gynaecol Obstet; 2000 Dec; 71(3):281-2. PubMed ID: 11102627
    [No Abstract]   [Full Text] [Related]  

  • 58. [The genetic sonogram].
    Ben-Ami M; Jadaon JE
    Harefuah; 2009 Jul; 148(7):455-9, 474. PubMed ID: 19848335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RETIRED: Fetal soft markers in obstetric ultrasound.
    Van den Hof MC; Wilson RD; ;
    J Obstet Gynaecol Can; 2005 Jun; 27(6):592-636. PubMed ID: 16100637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is there a role for nuchal translucency in the detection of rare chromosomal abnormalities in the era of noninvasive prenatal testing?
    Li YL; Li DZ
    Am J Obstet Gynecol; 2021 Oct; 225(4):463-464. PubMed ID: 34144021
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.